VRNA =MC $57 M--Cash $51 M--COPD Phase 2b results this month

Discussion in 'Stock picks and trading strategies' started by DollarChamp, Dec 4, 2019 at 8:34 AM.

  1. DollarChamp

    DollarChamp Member

    Market-cap $57 M --Cash $51 M --Shares Out 13.17 M --Great Pipeline -- Strong Insider & Institutional Ownership -- Phase 2b readout of the COPD trial is imminent (during this Q) ,positive results could push this extreme low float stock closer or even above $10 . Unsidocvered and brutally undepriced Stock with massive upside Potential here .GL

    Market-Cap $57 M
    Cash $51 M
    Price $3.90

    Shares Out 13.17 M


    "We are very pleased that our four-week Phase 2b dose-ranging clinical trial with nebulized ensifentrine is progressing according to plan and that we have completed enrollment of over 400 symptomatic patients with moderate to severe COPD. We anticipate completing this study around the end of 2019."


    Presentation (from late November)
    https://investors.veronapharma.com/static-files/9ed398c4-3150-4c0e-8fe3-1efe276fbffb


    Verona Pharma has compound with 'massive potential to impact lives of COPD and asthma patients'...02.12.2019
    https://www.biotech-capital.com/com...ives-of-copd-and-asthma-patients--908274.html


    Insider Buying
    https://www.lse.co.uk/DirectorsDeals.asp?shareprice=VRP&share=Verona-Pharma


    Top Shareholders :

    Vivo Capital, LLC ...1.5M
    OrbiMed ...1.3M
    New Enterprise ...1.2M
    Abingworth ...901.9K
    VenBio Partners LLC ...875.0K
    Novo Holdings A/S ...740.7K
    Andera Partners ...720.9K
    Aisling Capital ...443.6K
    Tekla Capital ...275.0K
    Arctic Fund ...120.4K


    [​IMG]

     

Share This Page